Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
Document Type
Article
Publication Date
1-16-2024
Publication Title
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN
1527-7755
First Page
2301569
Last Page
2301569
PubMed ID
38227898
Digital Object Identifier (DOI)
10.1200/JCO.23.01569
Recommended Citation
Motzer, Robert J; Porta, Camillo; Eto, Masatoshi; Powles, Thomas; Grünwald, Viktor; Hutson, Thomas E; Alekseev, Boris; Rha, Sun Young; Merchan, Jaime; Goh, Jeffrey C; Lalani, Aly-Khan A; De Giorgi, Ugo; Melichar, Bohuslav; Hong, Sung-Hoo; Gurney, Howard; Méndez-Vidal, María José; Kopyltsov, Evgeny; Tjulandin, Sergei; Gordoa, Teresa Alonso; Kozlov, Vadim; Alyasova, Anna; Winquist, Eric; Maroto, Pablo; Kim, Miso; Peer, Avivit; Procopio, Giuseppe; Takagi, Toshio; Wong, Shirley; Bedke, Jens; Schmidinger, Manuela; Rodriguez-Lopez, Karla; Burgents, Joseph; He, Cixin; Okpara, Chinyere E; McKenzie, Jodi; Choueiri, Toni K; and Galamaga, Rob, "Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study." (2024). ENT and Skull Base Surgery. 21.
https://scholar.barrowneuro.org/ent-and-skull-base-surgery/21